Meningioma
Conditions
Brief summary
Aggressive growing meningiomas resistant to multiple surgeries and radiotherapy constitute an unmet pharmaceutical need in neurooncology, leading to a fatal issue within a few months. Grade II-III meningiomas progression-free survival (PFS) 6 is at 10-15%. Median PFS grade III meningioma is approximate 3 years. Alpelisib is a well-tolerated Phosphoinositide 3-kinase α (Pi3Kα) specific inhibitor. However, phosphatidylinositol-3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) inhibition does not induce apoptosis in vitro and induces an antiproliferative effect without any radiologic response in most treated patients. Trametinib, a mekinist (MEK) inhibitor is currently used in combined treatment for recurrent melanomas in clinical practice with a good clinical tolerance at 1-2 mg daily. In vitro, on meningioma primary cell culture, Trametinib induces cell apoptosis via caspase activity. These results strongly suggest the relevance to combine Alpelisib and Trametinib in aggressive and recurrent meningiomas. Alpelisib and Trametinib combination has not been studied to date, despite each drugs have been separately studied in phase 3. Multicenter, open label, dose-finding phase I study of Alpelisib in combination with Trametinib administered at a fixed dose (1.5 mg daily), both drugs will be administered daily. Starting dose of Alpelisib will be 160mg/day and will be increased to 200mg/day or decreased to 120mg/day depending of grade 3-4 adverse events occurrence, to determine maximal tolerated dose (MTD) and recommended dose. Primary Objective is to determine the safety profile and tolerability of Alpelisib and Trametinib given in combination in patients with aggressive and refractory meningiomas in terms of Dose-Limiting Toxicities (DLT, assessed during cycle 1).
Interventions
DRUGTrametinib
Trametinib administered at a fixed dose (1.5 mg daily)
DRUGAlpelisib
A panel of 3 doses of ALPELISIB could be tested
BIOLOGICALBlood sample
Therapeutic biomarkers
DEVICEMRI
A MRI with contrast will be performed before treatment start. Assessment of tumor growth.
Sponsors
Assistance Publique Hopitaux De Marseille
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically proven meningioma grade I, II and III * Progression is defined as growing meningiomas on 2 different Magnetic Resonance Imaging (MRI) 3 to 6 months apart * Patients must have failed surgery, and not amenable to a new curative intended surgery * Patients must have failed radiotherapy and/or radiosurgery * Patients who have given their written consent * No contra indication to Alpelisib and Trametinib * No receiving other investigational agents * Written informed consent * Adequate bone marrow function * Adequate liver function as shown by * Adequate renal function
Exclusion criteria
* Contra indication to Alpelisib and Trametinib * Women of child-bearing age who are using no effective means of contraception * Pregnant or breast-feeding women * Patients receiving other investigational agents * Known intolerance or hypersensitivity to Alpelisib and Trametinib * Uncontrolled diabetes mellitus * Patients who have any severe and uncontrolled medical condition * Patients receiving chronic treatment with immunosuppressives * Patients with a known history of HIV seropositivity * Patients who have a history of another primary malignancy less than or equal to 3 years, with * the exceptions of non-melanoma skin cancer, and carcinoma in situ of uterine cervix
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Limiting Toxicity (DLT) rate of combination Alpelisib and Trametinib | 36 months | Evaluate adverse events graded (toxicity) according to National Cancer Institute's Common Toxicity Criteria (version 4.0). |
Countries
France
Contacts
Primary ContactThomas GRAILLON, PH
Backup ContactOlivier CHINOT, PU-PH
Outcome results
None listed